As such, clinical implementation of therapeutic agents targeting ErbB2, including trastuzumab and lapatinib, has achieved remarkable benefits in patients with ErbB2-overexpressing breast cancer; however, the development of resistance to these novel agents is emerging as a significant clinical challenge. The gene discussed is ERBB2; the disease is breast carcinoma.